losartan-potassium and Hematemesis

losartan-potassium has been researched along with Hematemesis* in 1 studies

Other Studies

1 other study(ies) available for losartan-potassium and Hematemesis

Article	Year
[Antibodies against human recombinant erythropoietin: an unusual cause of erythropoietin resistance]. Nephrologie, 2002, Volume: 23, Issue:1 In a 70 year old man with primary glomerulonephritis, severe anemia occurred after 4 years on hemodialysis and rHu-EPO. The usual mechanisms of EPO-resistance were excluded. A bone marrow sample showed red all aplasia. No circulating EPO could be detected; the serum inhibited the growth of erythroid precursors in bone marrow cultures. Immunoprecipitation identified an IgG anti-EPO, still active against deglycosylated EPO, i.e. directed against the peptidic matrix. Its high neutralising capacity and the absence of any immune abnormality rule out an auto-antibody. Anti-rHu EPO immunisation is a very rare occurrence, made severe by transfusion-dependence and the risk of hemosiderosis. An immuno-modulating treatment can therefore be justified. Topics: Aged; Anemia; Angiodysplasia; Blood Transfusion; Bone Marrow; Cell Division; Combined Modality Therapy; Digestive System; Drug Resistance; Erythroid Precursor Cells; Erythropoietin; Granulocyte-Macrophage Colony-Stimulating Factor; Hematemesis; Humans; Immunoglobulin G; Isoantibodies; Kidney Failure, Chronic; Leukemia, Erythroblastic, Acute; Male; Melena; Recombinant Proteins; Renal Dialysis; Tumor Cells, Cultured	2002

Article

Year

[Antibodies against human recombinant erythropoietin: an unusual cause of erythropoietin resistance].

Nephrologie, 2002, Volume: 23, Issue:1

In a 70 year old man with primary glomerulonephritis, severe anemia occurred after 4 years on hemodialysis and rHu-EPO. The usual mechanisms of EPO-resistance were excluded. A bone marrow sample showed red all aplasia. No circulating EPO could be detected; the serum inhibited the growth of erythroid precursors in bone marrow cultures. Immunoprecipitation identified an IgG anti-EPO, still active against deglycosylated EPO, i.e. directed against the peptidic matrix. Its high neutralising capacity and the absence of any immune abnormality rule out an auto-antibody. Anti-rHu EPO immunisation is a very rare occurrence, made severe by transfusion-dependence and the risk of hemosiderosis. An immuno-modulating treatment can therefore be justified.

Topics: Aged; Anemia; Angiodysplasia; Blood Transfusion; Bone Marrow; Cell Division; Combined Modality Therapy; Digestive System; Drug Resistance; Erythroid Precursor Cells; Erythropoietin; Granulocyte-Macrophage Colony-Stimulating Factor; Hematemesis; Humans; Immunoglobulin G; Isoantibodies; Kidney Failure, Chronic; Leukemia, Erythroblastic, Acute; Male; Melena; Recombinant Proteins; Renal Dialysis; Tumor Cells, Cultured

2002